First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study

BACKGROUND: Avelumab (anti-programmed death ligand 1 (PD-L1)) is approved in multiple countries for the treatment of metastatic Merkel cell carcinoma (mMCC), a rare and aggressive skin cancer. We report efficacy and safety data and exploratory biomarker analyses from a cohort of patients with mMCC t...

Descripción completa

Detalles Bibliográficos
Autores principales: D'Angelo, Sandra P, Lebbé, Celeste, Mortier, Laurent, Brohl, Andrew S, Fazio, Nicola, Grob, Jean-Jacques, Prinzi, Natalie, Hanna, Glenn J, Hassel, Jessica C, Kiecker, Felix, Georges, Sara, Ellers-Lenz, Barbara, Shah, Parantu, Güzel, Gülseren, Nghiem, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311489/
https://www.ncbi.nlm.nih.gov/pubmed/34301810
http://dx.doi.org/10.1136/jitc-2021-002646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311489/
https://www.ncbi.nlm.nih.gov/pubmed/34301810
http://dx.doi.org/10.1136/jitc-2021-002646

Ejemplares similares